The World Health Organisation (WHO) recommends screening for G6PD deficiency before prescribing primaquine with a threshold for prescribing the drug set at 30% G6PD activity, a level amenable to qualitative diagnostics [12]. Here, G6PD is linked to G6PD deficiency.